Pediatric Hematology-Immunology and Rheumatology Department, APHP-Centre Université de Paris (CUP), Necker Hospital, Paris, France.
French National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Pediatr Allergy Immunol. 2022 Jun;33(6):e13820. doi: 10.1111/pai.13820.
Several primary immunodeficiencies are caused by defects in the general DNA repair machinery as exemplified by the T-B- radiosensitive SCID condition owing to impaired resolution of programmed DNA double-strand breaks introduced by RAG1/2 during V(D)J recombination. The genome instability generally associated with these conditions results in an increased propensity to develop malignancies requiring genotoxic-based anti-cancer treatments. Moreover, the extent of immune deficiency often calls for hematopoietic stem cell transplantation as a definitive treatment, also requiring genotoxic-based conditioning regimen prior to transplantation. In both cases, the underlying general DNA repair defect may result in catastrophic iatrogenic consequences. It is, therefore, of paramount importance to assess the functionality of the DNA repair apparatus prior to any genotoxic treatment when the exact molecular cause of the disease is unknown. For this purpose, two simple assays can be used on patients derived peripheral blood lymphocytes: (1) the PROMIDISα biomarker, based on the next-generation sequencing analysis of the TCRα repertoire, will highlight specific signatures of DNA repair deficiencies; (2) direct analysis of the sensitivity of peripheral lymphocytes to ionizing radiation will formally identify patients at risk to develop toxicity toward genotoxic-based treatments.
几种原发性免疫缺陷是由一般 DNA 修复机制的缺陷引起的,例如由于 RAG1/2 在 V(D)J 重组过程中引入的程序性 DNA 双链断裂的解决能力受损而导致的 T-B-射线敏感 SCID 病症。这些病症通常与基因组不稳定性相关,导致恶性肿瘤的易发性增加,需要基于遗传毒性的抗癌治疗。此外,免疫缺陷的程度通常需要进行造血干细胞移植作为明确的治疗方法,在移植前也需要基于遗传毒性的预处理方案。在这两种情况下,潜在的一般 DNA 修复缺陷可能导致灾难性的医源性后果。因此,在确切的疾病分子病因未知的情况下,在任何遗传毒性治疗之前,评估 DNA 修复装置的功能至关重要。为此,可以在患者来源的外周血淋巴细胞上使用两种简单的检测:(1)PROMIDISα 生物标志物,基于 TCRα 库的下一代测序分析,将突出显示 DNA 修复缺陷的特定特征;(2)直接分析外周淋巴细胞对电离辐射的敏感性,将正式确定有发展为基于遗传毒性的治疗毒性风险的患者。